RenovoRx Q2 2025 revenue $422k from RenovoCath; DMC recommends continue Phase III trial

RenovoRx, Inc.

2025-Q2 EPS reported -$0.16 revenue$619,000

Q2 2025 revenue $422k from commercial RenovoCath sales, up from $0 in Q2 2024.
Cash $12.3M as of June 30, 2025; net loss $2.9M vs $2.4M YoY.
Independent DMC recommends continue Phase III TIGeR-PaC trial after second interim analysis; 95 patients randomized, 61 events.
13 cancer centers approved as customers (up from 5 in Q1); 4 have used device and placed repeat orders.
Hired Phil Stocton as Senior Director of Sales; launched PanTheR post-marketing registry study.

item 2.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.